tradingkey.logo

Inventiva SA

IVA
5.880USD
+0.080+1.38%
終値 02/06, 16:00ET15分遅れの株価
0.00時価総額
--直近12ヶ月PER

Inventiva SA

5.880
+0.080+1.38%

詳細情報 Inventiva SA 企業名

Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

Inventiva SAの企業情報

企業コードIVA
会社名Inventiva SA
上場日Feb 15, 2017
最高経営責任者「CEO」Obenshain (Andrew)
従業員数- -
証券種類Depository Receipt
決算期末- -
本社所在地50 rue de Dijon
都市DAIX
証券取引所NASDAQ OMX - NASDAQ BASIC
France
郵便番号21121
電話番号33380447500
ウェブサイトhttps://inventivapharma.com/
企業コードIVA
上場日Feb 15, 2017
最高経営責任者「CEO」Obenshain (Andrew)

Inventiva SAの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Director - Human Resources
Director - Human Resources
--
--
Ms. Martine Zimmerman
Ms. Martine Zimmerman
Independent Director
Independent Director
--
--
Dr. Annick Schwebig, M.D.
Dr. Annick Schwebig, M.D.
Independent Director
Independent Director
--
--
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Ms. Alice Roudot-Ketelers
Ms. Alice Roudot-Ketelers
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Eric Duranson
Mr. Eric Duranson
General Counsel
General Counsel
--
--
Ms. Pascaline Clerc
Ms. Pascaline Clerc
Executive Vice President - Strategy and Corporate Affairs
Executive Vice President - Strategy and Corporate Affairs
--
--
Dr. Mark Pruzanski, M.D.
Dr. Mark Pruzanski, M.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Director - Human Resources
Director - Human Resources
--
--
Ms. Martine Zimmerman
Ms. Martine Zimmerman
Independent Director
Independent Director
--
--
Dr. Annick Schwebig, M.D.
Dr. Annick Schwebig, M.D.
Independent Director
Independent Director
--
--
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Ms. Alice Roudot-Ketelers
Ms. Alice Roudot-Ketelers
Chief Operating Officer
Chief Operating Officer
--
--

収益内訳

会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。

株主

更新時刻: Mon, Feb 2
更新時刻: Mon, Feb 2
株主統計
種類
株主統計
株主統計
比率
Samsara BioCapital, LLC
3.73%
Deep Track Capital LP
2.27%
Yiheng Capital Management, L.P.
1.90%
UBS Financial Services, Inc.
1.90%
Polar Capital LLP
1.36%
他の
88.83%
株主統計
株主統計
比率
Samsara BioCapital, LLC
3.73%
Deep Track Capital LP
2.27%
Yiheng Capital Management, L.P.
1.90%
UBS Financial Services, Inc.
1.90%
Polar Capital LLP
1.36%
他の
88.83%
種類
株主統計
比率
Venture Capital
5.03%
Investment Advisor
3.90%
Hedge Fund
2.85%
Investment Advisor/Hedge Fund
1.38%
Research Firm
0.02%
他の
86.82%

機関投資家保有株

更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
29
15.17M
10.90%
+10.19M
2025Q3
21
4.95M
5.18%
+27.37K
2025Q2
19
4.87M
5.09%
-661.07K
2025Q1
21
4.87M
5.09%
-959.14K
2024Q4
21
5.45M
6.26%
-698.93K
2024Q3
20
4.86M
9.25%
-1.29M
2024Q2
21
4.85M
9.24%
-1.47M
2024Q1
22
4.85M
9.31%
-1.45M
2023Q4
19
4.86M
9.33%
-1.43M
2023Q3
22
4.86M
11.53%
-1.45M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
Samsara BioCapital, LLC
5.19M
3.73%
+5.19M
--
Nov 17, 2025
Yiheng Capital Management, L.P.
2.64M
1.9%
--
--
Sep 30, 2025
UBS Financial Services, Inc.
9.12K
0.01%
-18.33K
-66.77%
Sep 30, 2025
New Enterprise Associates (NEA)
1.46M
1.05%
--
--
Sep 30, 2025
BVF Partners L.P.
686.04K
0.49%
--
--
Nov 17, 2025
Millennium Management LLC
112.03K
0.08%
+112.03K
--
Sep 30, 2025
Commonwealth Financial Network
64.86K
0.05%
+10.54K
+19.40%
Sep 30, 2025
詳細を見る

関連ETF

銘柄名
比率
データなし

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
KeyAI